Jorge A Masso-Silva1,2, Alexander Moshensky1,2, Michael T Y Lam2,3, Mazen F Odish2, Arjun Patel1,2, Le Xu4, Emily Hansen5,4, Samantha Trescott5,4, Celina Nguyen5,4, Roy Kim5,4, Katherine Perofsky5,4, Samantha Perera1,2, Lauren Ma1,2, Josephine Pham1,2, Mark Rolfsen2, Jarod Olay1,2, John Shin1,2, Jennifer M Dan6,7, Robert K Abbott8,9, Sydney Ramirez6,7, Thomas H Alexander10, Grace Y Lin11, Ana Lucia Fuentes1,2, Ira Advani1,2, Deepti Gunge1,2, Victor Pretorius12, Atul Malhotra2, Xin Sun4, Jason Duran13, Mark Hepokoski2, Shane Crotty6,7, Nicole G Coufal5,4, Angela Meier14, Laura E Crotty Alexander1,2. 1. Pulmonary and Critical Care Section, Veterans Affairs San Diego Healthcare System, La Jolla, California, USA. 2. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 3. The Salk Institute, La Jolla, California, USA. 4. Department of Pediatrics, University of California, San Diego , La Jolla, California, USA. 5. Rady Children's Hospital, San Diego, California, USA. 6. Division of Infectious Diseases and Global Public Heath, Department of Medicine, University of California, San Diego , La Jolla, California, USA. 7. La Jolla Institute for Immunology, La Jolla, California, USA. 8. Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla , CA 92037, USA. 9. Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla , CA 92037, USA. 10. Division of Head and Neck Surgery, Scripps Clinic , La Jolla, California, USA. 11. Department of Pathology, University of California, San Diego , La Jolla, California, USA. 12. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of California, San Diego, La Jolla, California, USA. 13. Division of Cardiology, Department of Medicine, University of California, San Diego , La Jolla, California, USA. 14. Department of Anesthesiology, Division of Critical Care, University of California, San Diego , La Jolla, California, USA.
Abstract
BACKGROUND: Increased inflammation has been well defined in coronavirus disease 2019 (COVID-19), while definitive pathways driving severe forms of this disease remain uncertain. Neutrophils are known to contribute to immunopathology in infections, inflammatory diseases, and acute respiratory distress syndrome, a primary cause of morbidity and mortality in COVID-19. Changes in neutrophil function in COVID-19 may give insight into disease pathogenesis and identify therapeutic targets. METHODS: Blood was obtained serially from critically ill COVID-19 patients for 11 days. Neutrophil extracellular trap formation (NETosis), oxidative burst, phagocytosis, and cytokine levels were assessed. Lung tissue was obtained immediately postmortem for immunostaining. PubMed searches for neutrophils, lung, and COVID-19 yielded 10 peer-reviewed research articles in English. RESULTS: Elevations in neutrophil-associated cytokines interleukin 8 (IL-8) and interleukin 6, and general inflammatory cytokines IFN-inducible protien-19, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 1β, interleukin 10, and tumor necrosis factor, were identified both at first measurement and across hospitalization (P < .0001). COVID-19 neutrophils had exaggerated oxidative burst (P < .0001), NETosis (P < .0001), and phagocytosis (P < .0001) relative to controls. Increased NETosis correlated with leukocytosis and neutrophilia, and neutrophils and NETs were identified within airways and alveoli in lung parenchyma of 40% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected lungs available for examination (2 of 5). While elevations in IL-8 and absolute neutrophil count correlated with disease severity, plasma IL-8 levels alone correlated with death. CONCLUSIONS: Literature to date demonstrates compelling evidence of increased neutrophils in the circulation and lungs of COVID-19 patients. Importantly, neutrophil quantity and activation correlates with severity of disease. Similarly, our data show that circulating neutrophils in COVID-19 exhibit an activated phenotype with enhanced NETosis and oxidative burst. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
BACKGROUND: Increased inflammation has been well defined in coronavirus disease 2019 (COVID-19), while definitive pathways driving severe forms of this disease remain uncertain. Neutrophils are known to contribute to immunopathology in infections, inflammatory diseases, and acute respiratory distress syndrome, a primary cause of morbidity and mortality in COVID-19. Changes in neutrophil function in COVID-19 may give insight into disease pathogenesis and identify therapeutic targets. METHODS: Blood was obtained serially from critically ill COVID-19 patients for 11 days. Neutrophil extracellular trap formation (NETosis), oxidative burst, phagocytosis, and cytokine levels were assessed. Lung tissue was obtained immediately postmortem for immunostaining. PubMed searches for neutrophils, lung, and COVID-19 yielded 10 peer-reviewed research articles in English. RESULTS: Elevations in neutrophil-associated cytokines interleukin 8 (IL-8) and interleukin 6, and general inflammatory cytokines IFN-inducible protien-19, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 1β, interleukin 10, and tumor necrosis factor, were identified both at first measurement and across hospitalization (P < .0001). COVID-19 neutrophils had exaggerated oxidative burst (P < .0001), NETosis (P < .0001), and phagocytosis (P < .0001) relative to controls. Increased NETosis correlated with leukocytosis and neutrophilia, and neutrophils and NETs were identified within airways and alveoli in lung parenchyma of 40% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected lungs available for examination (2 of 5). While elevations in IL-8 and absolute neutrophil count correlated with disease severity, plasma IL-8 levels alone correlated with death. CONCLUSIONS: Literature to date demonstrates compelling evidence of increased neutrophils in the circulation and lungs of COVID-19 patients. Importantly, neutrophil quantity and activation correlates with severity of disease. Similarly, our data show that circulating neutrophils in COVID-19 exhibit an activated phenotype with enhanced NETosis and oxidative burst. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Authors: Kylie B R Belchamber; Onn S Thein; Jon Hazeldine; Frances S Grudzinska; Aduragbemi A Faniyi; Michael J Hughes; Alice E Jasper; Kay Por Yip; Louise E Crowley; Sebastian T Lugg; Elizabeth Sapey; Dhruv Parekh; David R Thickett; Aaron Scott Journal: Cells Date: 2022-09-16 Impact factor: 7.666
Authors: Ellen McKenna; Richard Wubben; Johana M Isaza-Correa; Ashanty M Melo; Aisling Ui Mhaonaigh; Niall Conlon; James S O'Donnell; Clíona Ní Cheallaigh; Tim Hurley; Nigel J Stevenson; Mark A Little; Eleanor J Molloy Journal: Front Immunol Date: 2022-06-01 Impact factor: 8.786
Authors: Rebecca Dowey; Joby Cole; A A Roger Thompson; Rebecca C Hull; Chenghao Huang; Jacob Whatmore; Ahmed Iqbal; Kirsty L Bradley; Joanne McKenzie; Allan Lawrie; Alison M Condliffe; Endre Kiss-Toth; Ian Sabroe; Lynne R Prince Journal: ERJ Open Res Date: 2022-04-04
Authors: Ben Morton; Kayla G Barnes; Jennifer Cornick; Kondwani C Jambo; Catherine Anscombe; Khuzwayo Jere; Prisca Matambo; Jonathan Mandolo; Raphael Kamng'ona; Comfort Brown; James Nyirenda; Tamara Phiri; Ndaziona P Banda; Charlotte Van Der Veer; Kwazizira S Mndolo; Kelvin Mponda; Jamie Rylance; Chimota Phiri; Jane Mallewa; Mulinda Nyirenda; Grace Katha; Paul Kambiya; James Jafali; Henry C Mwandumba; Stephen B Gordon Journal: Nat Commun Date: 2021-06-11 Impact factor: 14.919